Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShield Thera Regulatory News (STX)

Share Price Information for Shield Thera (STX)

Share Price is delayed by 15 minutes
Get Live Data
5.75    -0.10 (-1.71%)
Bid:
5.70
Ask:
5.80
Spread: 0.10 (1.754%)
Market Cap: £61.50m
STX Live PriceLast checked at - London Stock Exchange

Intraday Shield Thera Share Chart

Form 8.3 - Shield Therapeutics plc

9 May 2023 11:04

Form 8.3 - Shield Therapeutics plc

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:Jupiter Fund Management Plc
(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. 
(c) Name of offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offereeShield Therapeutics plc
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: 
(e) Date position held: For an opening position disclosure, state the latest practicable date prior to the disclosure5th May 2023
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer? If it is a cash offer or possible cash offer, state “N/A”No

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:1.5p Ordinary
 InterestsShort positions
 Number%Number%
(1) Relevant securities owned and/or controlled:37,146,9926.34  
(2) Cash-settled derivatives:    
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:    
TOTAL:37,146,9926.34  

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:None
Details, including nature of the rights concerned and relevant percentages:None

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant securityPurchase/saleNumber of securitiesPrice per unit
None   

(b) Cash-settled derivative transactions

Class of relevant securityProduct descriptione.g. CFDNature of dealinge.g. opening/closing a long/short position, increasing/reducing a long/short positionNumber of reference securitiesPrice per unit
NONE    
     

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant securityProduct description e.g. call optionWriting, purchasing, selling, varying etc.Number of securities to which option relatesExercise price per unitTypee.g. American, European etc.Expiry dateOption money paid/ received per unit
NONE       

(ii) Exercise

Class of relevant securityProduct descriptione.g. call optionExercising/ exercised againstNumber of securitiesExercise price per unit
NONE    

(d) Other dealings (including subscribing for new securities)

Class of relevant securityNature of dealinge.g. subscription, conversionDetailsPrice per unit (if applicable)
None   

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”
NONE

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:(i) the voting rights of any relevant securities under any option; or (ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:If there are no such agreements, arrangements or understandings, state “none”
NONE

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?NO

Date of disclosure:9th May 2023
Contact name:Jon Watson
Telephone number:0203 817 1672

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Date   Source Headline
10th Dec 202011:05 amRNSSecond Price Monitoring Extn
10th Dec 202011:00 amRNSPrice Monitoring Extension
10th Dec 20207:00 amRNSUpdate re US partnering discussions
30th Nov 20207:00 amRNSHolding(s) in Company
30th Nov 20207:00 amRNSTotal Voting Rights Update
2nd Nov 20207:00 amRNSTotal Voting Rights Update
19th Oct 20207:00 amRNSWithdrawal of all oppositions by TEVA
30th Sep 20201:21 pmRNSBlock Listing 6 Monthly Return
30th Sep 20201:20 pmRNSTotal Voting Rights Update
18th Sep 20201:30 pmEQSHardman & Co Research: Shield Therapeutics (STX): Optimism over US deal
16th Sep 20207:00 amRNSHalf-year Report
14th Sep 20207:00 amRNSNotice of Results
28th Aug 202012:21 pmRNSTotal Voting Rights Update
6th Aug 20202:21 pmRNSAEGIS-H2H study reanalysis
31st Jul 20207:00 amRNSTotal Voting Rights update
16th Jul 20207:00 amRNSPT20 paper publication
30th Jun 20207:00 amRNSTotal Voting Rights Update
26th Jun 20207:00 amRNSAppointment of Non-Executive Director
18th Jun 20203:18 pmRNSResults of 2020 Annual General Meeting
3rd Jun 20207:00 amRNSFeraccru®/Accrufer® publications
29th May 202011:25 amRNSTotal Voting Rights Update
28th May 20207:00 amRNSInvestor presentations
26th May 20207:00 amRNSAppointment of Chairman
22nd May 20204:15 pmRNS2019 Annual Report and 2020 AGM Notice
21st May 20204:40 pmRNSSecond Price Monitoring Extn
21st May 20204:35 pmRNSPrice Monitoring Extension
21st May 20207:00 amRNSPreliminary Results
19th May 20207:00 amRNSNotice of Results
11th May 20201:15 pmEQSHardman & Co Research: Shield Therapeutics (STX): Reassuring trading update
1st May 20207:00 amRNSBusiness and trading update
30th Apr 20205:23 pmRNSTotal Voting Rights Update
27th Apr 20207:00 amRNSFurther re. Directorate Change
22nd Apr 20207:00 amRNSDirectorate Change
26th Mar 20204:42 pmRNSSecond Price Monitoring Extn
26th Mar 20204:36 pmRNSPrice Monitoring Extension
20th Mar 202011:36 amRNSHolding(s) in Company
17th Mar 20202:06 pmRNSSecond Price Monitoring Extn
17th Mar 20202:00 pmRNSPrice Monitoring Extension
17th Mar 20207:00 amRNSAEGIS-H2H study update
6th Mar 20207:00 amRNSInvestor Presentation
2nd Mar 20204:41 pmRNSBlock Listing Application
21st Feb 202011:14 amRNSHolding(s) in Company
28th Jan 202012:15 pmEQSHardman & Co Research: Shield Therapeutics (STX): Good demand for Feraccru in Europe
27th Jan 20207:00 amRNSBusiness and trading update
24th Jan 20207:00 amRNSInvestor presentations
14th Jan 20207:15 amEQSHardman & Co Research: Shield Therapeutics (STX): Taking on China
8th Jan 20207:00 amRNSChina licence agreement for Feraccru/Accrufer
12th Dec 20195:30 pmRNSEland Oil & Gas
29th Nov 20193:31 pmRNSHolding(s) in Company
25th Nov 20197:00 amRNSQCA Corporate Governance Code

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.